Patrick R. Hagner

1.9k total citations
51 papers, 905 citations indexed

About

Patrick R. Hagner is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Patrick R. Hagner has authored 51 papers receiving a total of 905 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 24 papers in Hematology and 23 papers in Oncology. Recurrent topics in Patrick R. Hagner's work include Protein Degradation and Inhibitors (21 papers), Multiple Myeloma Research and Treatments (19 papers) and Lymphoma Diagnosis and Treatment (19 papers). Patrick R. Hagner is often cited by papers focused on Protein Degradation and Inhibitors (21 papers), Multiple Myeloma Research and Treatments (19 papers) and Lymphoma Diagnosis and Treatment (19 papers). Patrick R. Hagner collaborates with scholars based in United States, Switzerland and Canada. Patrick R. Hagner's co-authors include Ronald B. Gartenhaus, Krystyna Mazan-Mamczarz, Anita K. Gandhi, Abraham Schneider, Bojie Dai, Rajesh Chopra, Kevin G. Becker, Anjan Thakurta, Chad C. Bjorklund and Suzana S. Couto and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Patrick R. Hagner

48 papers receiving 894 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick R. Hagner United States 16 671 271 253 166 131 51 905
Bangzheng Chen United States 6 584 0.9× 320 1.2× 430 1.7× 114 0.7× 155 1.2× 8 900
Teresa Paíno Spain 14 443 0.7× 227 0.8× 333 1.3× 96 0.6× 63 0.5× 31 629
A M Martelli Italy 10 580 0.9× 191 0.7× 198 0.8× 58 0.3× 89 0.7× 17 785
Lourdes Mendez United States 10 309 0.5× 218 0.8× 104 0.4× 191 1.2× 190 1.5× 34 609
Janine Haug United States 7 392 0.6× 197 0.7× 206 0.8× 71 0.4× 65 0.5× 10 529
Mahan Abbasian United States 9 637 0.9× 281 1.0× 431 1.7× 78 0.5× 132 1.0× 13 830
Cory Mavis United States 16 441 0.7× 285 1.1× 77 0.3× 245 1.5× 120 0.9× 74 754
Monica Ceccon Italy 13 311 0.5× 295 1.1× 115 0.5× 133 0.8× 87 0.7× 20 650
K. Martin Kortuem United States 10 667 1.0× 276 1.0× 557 2.2× 53 0.3× 65 0.5× 20 853
Emmanuelle Ménoret France 10 444 0.7× 160 0.6× 194 0.8× 60 0.4× 119 0.9× 14 574

Countries citing papers authored by Patrick R. Hagner

Since Specialization
Citations

This map shows the geographic impact of Patrick R. Hagner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick R. Hagner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick R. Hagner more than expected).

Fields of papers citing papers by Patrick R. Hagner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick R. Hagner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick R. Hagner. The network helps show where Patrick R. Hagner may publish in the future.

Co-authorship network of co-authors of Patrick R. Hagner

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick R. Hagner. A scholar is included among the top collaborators of Patrick R. Hagner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick R. Hagner. Patrick R. Hagner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nakayama, Yumi, Lei Wu, N. Kumari, et al.. (2024). Golcadomide Extends Survival of Lymphoma GEMM Mice in Combination with a CD20xCD3 T-Cell Bispecific through Increased T-Cell Activation and Infiltration. Blood. 144(Supplement 1). 1617–1617. 1 indexed citations
2.
3.
Jeyaraju, Danny V., et al.. (2023). Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway. Blood. 142(Supplement 1). 1434–1434.
4.
Zhang, Mingjun, Ian Cushman, Henry Lik‐Yuen Chan, et al.. (2023). A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma. Modern Pathology. 36(4). 100050–100050. 2 indexed citations
5.
Hagner, Patrick R., Hsiling Chiu, Martino Colombo, et al.. (2022). Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL. Clinical Cancer Research. 28(15). 3367–3377. 3 indexed citations
6.
Jeyaraju, Danny V., Sheida Hayati, Ann Polonskaia, et al.. (2022). Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial. Blood. 140(Supplement 1). 3865–3867. 1 indexed citations
7.
Bjorklund, Chad C., Michael Amatangelo, Hsiling Chiu, et al.. (2021). Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma. Blood. 138(Supplement 1). 1613–1613. 6 indexed citations
8.
Risueño, Alberto, Patrick R. Hagner, Fadi Towfic, et al.. (2020). Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. Blood. 135(13). 1008–1018. 11 indexed citations
9.
Mehta–Shah, Neha, Julio C. Chávez, Pau Abrisqueta, et al.. (2020). Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.. Journal of Clinical Oncology. 38(15_suppl). 3501–3501. 2 indexed citations
10.
Rasco, Drew, Kyriakos P. Papadopoulos, Michael Pourdehnad, et al.. (2018). A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clinical Cancer Research. 25(1). 90–98. 74 indexed citations
11.
12.
Bjorklund, Chad C., Ling Lu, Jian Kang, et al.. (2015). Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer Journal. 5(10). e354–e354. 154 indexed citations
13.
Dai, Bojie, Xia Zhao, Krystyna Mazan-Mamczarz, et al.. (2011). Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nature Communications. 2(1). 402–402. 50 indexed citations
14.
Hagner, Patrick R., Krystyna Mazan-Mamczarz, Eric M. Balzer, et al.. (2010). Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5′ terminal oligopyrimidine tract. Oncogene. 30(13). 1531–1541. 41 indexed citations
15.
Hagner, Patrick R., Abraham Schneider, & Ronald B. Gartenhaus. (2010). Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood. 115(11). 2127–2135. 74 indexed citations
16.
Dai, Bojie, X. Frank Zhao, Patrick R. Hagner, et al.. (2009). Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma. Cancer Research. 69(19). 7835–7843. 23 indexed citations
17.
Mazan-Mamczarz, Krystyna, Patrick R. Hagner, Bojie Dai, et al.. (2008). Identification of Transformation-Related Pathways in a Breast Epithelial Cell Model Using a Ribonomics Approach. Cancer Research. 68(19). 7730–7735. 37 indexed citations
18.
Mazan-Mamczarz, Krystyna, et al.. (2008). Targeted suppression of MCT-1 attenuates the malignant phenotype through a translational mechanism. Leukemia Research. 33(3). 474–482. 16 indexed citations
19.
Mazan-Mamczarz, Krystyna, Patrick R. Hagner, Subramanya Srikantan, et al.. (2008). Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene. 27(47). 6151–6163. 98 indexed citations
20.
Nandi, Sumon, et al.. (2006). Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage. Oncogene. 26(16). 2283–2289. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bangzheng Chen Breakdown of academic impact, for papers by Teresa Paíno Breakdown of academic impact, for papers by A M Martelli Breakdown of academic impact, for papers by Lourdes Mendez Breakdown of academic impact, for papers by Janine Haug Breakdown of academic impact, for papers by Mahan Abbasian Breakdown of academic impact, for papers by Cory Mavis Breakdown of academic impact, for papers by Monica Ceccon Breakdown of academic impact, for papers by K. Martin Kortuem Breakdown of academic impact, for papers by Emmanuelle Ménoret
Rankless by CCL
2026